Strategies for studying cardiovascular phenotypes in genetically manipulated mice

Hypertension

Volumn 27, Issue 3 II, 1996, Pages 495-501

  Becker, K David ^a   Gottshall, Kim R ^a   Chien, Kenneth R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

animals, transgenic; gene targeting; mice, inbred strains; mice, knockout; models, cardiovascular; myocardium

Indexed keywords

CONFERENCE PAPER; GENE EXPRESSION; GENE TARGETING; HYPERTENSION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0029983366     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.27.3.495     Document Type: Conference Paper

References (66)

1. Paigen K. A miracle enough: the power of mice. Nat Med. 1995;1: 215-220.
2. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell. 1993;75:631-639.
3. Doevendans PA, Hunter JJ, Lembo G, Wollert KC, Chien KR. Strategies for studying cardiovascular diseases in transgenic and gene-targeted mice. In: Monastersky GM, Robl JM, eds. Strategies in Transgenic Animal Science. Washington, DC: American Society for Microbiology; 1995:107-144.
4. Chien KR. Genes and physiology: molecular physiology in genetically engineered animals. J Clin Invest. In press.
5. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
6. Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci U S A. 1991;88:434-438.
7. Shimano H, Yamada N, Katsuki M, Shimada M, Gotoda T, Harada K, Murase T, Fukazawa C, Takaku F, Yazaki Y. Overexpression of apolipoprotein E in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia. Proc Natl Acad Sci U S A. 1992; 89:1750-1754.
8. Milano CA, Allen LF, Dolber PC, Johnson TD, Rockman HA, Bond RA, Lefkowitz RJ. Marked enhancement in myocardial function resulting from overexpression of a human beta-adrenergic receptor gene. J Thorac Cardiovasc Surg. 1995;109:236-241.
9. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF, Lefkowitz RJ. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor [see comments]. Nature. 1995;374:272-276.
10. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science. 1995;268:1350-1353.
11. Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch R. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell. 1993;75:1351-1359.
12. Braun T, Arnold HH. Inactivation of Myf-6 and Myf-5 genes in mice leads to alterations in skeletal muscle development. EMBO J. 1995;14:1176-1186.
13. Buckingham ME, Lyons GE, Ott MO, Sassoon DA. Myogenesis in the mouse. Ciba Found Symp. 1992;165:111-124; discussion 124-131.
14. Litvin J, Montgomery MO, Goldhamer DJ, Emerson CJ, Bader DM. Identification of DNA-binding protein(s) in the developing heart. Dev Biol. 1993;156:409-417.
15. Miner JH, Miller JB, Wold BJ. Skeletal muscle phenotypes initiated by ectopic MyoD in transgenic mouse heart. Development. 1992;114:853-860.
16. Santerre RF, Bales KR, Janney MJ, Hannon K, Fisher LF, Bailey CS, Morris J, Ivarie R, Smith CK 2nd. Expression of bovine myf=5 induces ectopic skeletal muscle formation in transgenic mice. Mol Cell Biol. 1993;13:6044-6051.
17. Hunter JJ, Tanaka N, Rockman HR, Ross J JR, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 1995;270:23173-23178.
18. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 1994;8: 1897-1909.
19. Henderson SA, Spencer M, Sen A, Kumar C, Siddiqui MA, Chien KR. Structure, organization, and expression of the rat cardiac myosin light chain-2 gene: identification of a 250-base pair fragment which confers cardiac-specific expression. J Biol Chem. 1989;264: 18142-18148.
20. Lee KJ, Hickey R, Zhu H, Chien KR. Positive regulatory elements (HF-1a and HF-1b) and a novel negative regulatory element (HF-3) mediate ventricular muscle-specific expression of myosin light-chain 2-luciferase fusion genes in transgenic mice. Mol Cell Biol. 1994;14:1220-1229.
21. Lyons GE. In situ analysis of the cardiac muscle gene program during embryogenesis. Trends Cardiovasc Med. 1994;4:70-77.
22. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268:1766-1769.
23. Dunwoodie SL, Joya JE, Arkell RM, Hardeman EC. Multiple regions of the human cardiac actin gene are necessary for maturation-based expression in striated muscle. J Biol Chem. 1994; 269:12212-12219.
24. Robbins J, Palermo J, Rindt H. In vivo definition of a cardiac specific promoter and its potential utility in remodeling the heart. Ann N Y Acad Sci. 1995;752:492-505.
25. Huang MT, Gorman CM. Intervening sequences increase efficiency of RNA 3′ processing and accumulation of cytoplasmic RNA. Nucleic Acids Res. 1990;18:937-947.
26. Choi T, Huang M, Gorman C, Jaenisch R. A generic intron increases gene expression in transgenic mice. Mol Cell Biol. 1991;11: 3070-3074.
27. Bronson SK, Smithies O. Altering mice by homologous recombination using embryonic stem cells. J Biol Chem. 1994;269: 27155-27158.
28. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154-156.
29. Gordon RD. Heterogeneous hypertension. Nat Genet. 1995;11:6-9.
30. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
31. Smithies O, Kim HS. Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci U S A. 1994;91:3612-3615.
32. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A. 1995;92:2735-2739.
33. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
34. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O'Brien DA, Smithies O. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature. 1995;375:146-148.
35. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting [see comments]. Science. 1994;265:103-106.
36. Cui C, Wani MA, Wight D, Kopchick J, Stambrook PJ. Reporter genes in transgenic mice. Transgenic Res. 1994;3:182-194.
37. Liska DJ, Reed MJ, Sage EH, Bornstein P. Cell-specific expression of alpha 1(I) collagen-hGH minigenes in transgenic mice. J Cell Biol. 1994;125:695-704.
38. Banerjee SA, Roffler-Tarlov S, Szabo M, Frohman L, Chikaraishi DM. DNA regulatory sequences of the rat tyrosine hydroxylase gene direct correct catecholaminergjc cell-type specificity of a human growth hormone reporter in flie CNS of transgenic mice causing a dwarf phenotype. Mol Brain Res. 1994;24:89-106.
39. Crenshaw EB, Kalla K, Simmons DM, Swanson LW, Rosenfeld MG. Cell-specific expression of the prolactin gene in transgenic mice is controlled by synergistic interactions between promoter and enhancer elements. Genes Dev. 1989;3:959-972.
40. Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982;2:1044-1051.
41. Pothier F, Ouellet M, Julien JP, Guerin SL. An improved CAT assay for promoter analysis in either transgenic mice or tissue culture cells. DNA Cell Biol. 1992;11:83-90.
42. Donoghue MJ, Alvarez JD, Merlie JP, Sanes JR. Fiber type- and position-dependent expression of a myosin light chain-CAT transgene detected with a novel histochemical stain for CAT. J Cell Biol. 1991;115:423-434.
43. Alam J, Cook JL. Reporter genes: application to the study of mammalian gene transcription. Anal Biochem. 1990;188:245-254.
44. Fire A. Histochemical techniques for locating Escherichia coli beta-galactosidase activity in transgenic organisms. Genet Anal Tech Appl. 1992;9:151-158.
45. Nicholson EB, Concaugh EA, Mobley HL, Proteus mirabilis urease: use of a ureA-lacZ fusion demonstrates that induction is highly specific for urea. Infect Immun. 1991;59:3360-3365.
46. Bonnerot C, Grimber G, Briand P, Nicolas JF. Patterns of expression of position-dependent integrated transgenes in mouse embryo. Proc Natl Acad Sci U S A. 1990;87:6331-6335.
47. Smeyne RJ, Curran T, Morgan JI. Temporal and spatial expression of a fos-LacZ transgene in the developing nervous system. Brain Res Mol Brain Res. 1992;16:158-162.
48. Smeyne RJ, Schilling K, Robertson L, Luk D, Oberdick J, Curran T, Morgan JI. fos-LacZ transgenic mice: mapping sites of gene induction in the central nervous system. Neuron. 1992;8:13-23.
49. Belecky AT, Wight DC, Kopchick JJ, Parysek LM. Intragenic sequences are required for cell type-specific and injury-induced expression of the rat peripherin gene. J Neurosci. 1993;13: 5056-5065.
50. Prasher DC, Eckenrode VK, Ward WW, Prendergast FG, Cormier MJ. Primary structure of the Aequorea victoria green-fluorescent protein. Gene. 1992;111:229-233.
51. Wang S, Hazelrigg T. Implications for bed mRNA localization from spatial distribution of exu protein in Drosophila oogenesis. Nature. 1994;369:400-403.
52. Hodgkinson S. GFP in Dictyostelium. Trends Genet. 1995;11: 327-328.
53. Haseloff J, Amos B. GFP in plants. Trends Genet. 1995;11:328-329.
54. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. Science. 1994; 263:802-805.
55. Brand A. GFP in Drosophila. Trends Genet. 1995;11:324-325.
56. Pines J. GFP in mammalian cells. Trends Genet. 1995;11:326-327.
57. Ikawa M, Kominami K, Yoshimura Y, Tanaka K, Nishimune Y, Okabe M. Green fluorescent protein as a marker in transgenic mice. Dev Growth Different. 1995;37:455-459.
58. Ropp JD, Donahue CJ, Kimball DW, Hooley JJ, Chin JYW, Hoffman RA, Cuthbertson RA, Bauer KD. Aequorea green fluorescent protein (GFP) analysis by flow cytometry. Cytometry. In press.
59. Rockman HA, Knowlton KU, Ross J Jr, Chien KR. In vivo murine cardiac hypertrophy: a novel model to identify genetic signaling mechanisms that activate an adaptive physiological response. Circulation. 1993;87(suppl VII):VII-14-VII-21.
60. Rockman HA, Ono S, Ross RS, Jones LR, Karimi M, Bhargava V, Ross J Jr, Chien KR. Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad Sci U S A. 1994;91: 2694-2698.
61. Lin MC, Rockman HA, Chien KR. Heart and lung disease in engineered mice. Nat Med. 1995;1:749-751.
62. Hoit BD, Khoury SF, Kranias EG, Ball N, Walsh RA. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res. 1995;77:632-637.
63. Knowlton KU, Rockman HA, Itani M, Vovan A, Seidman CE, Chien KR. Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium. J Clin Invest. 1995;96:1311-1318.
64. Schlaeger TM, Qin Y, Fujiwara Y, Magram J, Sato TN. Vascular endothelial cell lineage-specific promoter in transgenic mice. Development. 1995;121:1089-1098.
65. Kelly R, Alonso S, Tajbakhsh S, Cossu G, Buckingham M. Myosin light chain 3F regulatory sequences confer regionalized cardiac and skeletal muscle expression in transgenic mice. J Cell Biol. 1995;129: 383-396.
66. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuy JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 1992;360:670-672.